All pathogenic germline mutations in BRCA1 (n = 31) and BRCA2 (n = 16), known prior to smMIP‐based targeted sequencing, were called by the NextSeq software in 47 tumor samples derived from 38 patients (Fig. 2A). This evidence concerns the gene BRCA1 and neoplasm.